Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508647 | 0.92 | USP2 (0.38) | CYP11B1CYP11B2CYP1A2TSHR | |
| SCHEMBL24713778 | 0.86 | USP2 (0.36) | CYP11B1CYP11B2CYP1A2TSHR | |
| SCHEMBL24713161 | 0.86 | USP2 (0.36) | CYP11B1CYP11B2CYP1A2TSHR | |
| SCHEMBL23509081 | 0.86 | USP2 (0.36) | CYP11B1CYP11B2TSHR | |
| SCHEMBL15451904 | 0.86 | USP2 (0.36) | CYP11B1CYP11B2CYP1A2TSHR | |
| SCHEMBL4406755 | 0.86 | USP2 (0.33) | — | |
| SCHEMBL14154426 | 0.85 | CYP1A2 (0.37) | CYP1A2TSHR | |
| SCHEMBL12049772 | 0.82 | TSHR (0.33) | CYP11B1CYP11B2CYP1A2TSHR | |
| SCHEMBL15431970 | 0.78 | — | — | |
| SCHEMBL357308 | 0.76 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4328228-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4289857-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4282416-A2 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023225634-A2 | METHODS FOR THE ENHANCEMENT OF THERAPEUTIC EFFECT OF CAR-T CELLS | IMAGO BIOSCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| EP-2038264-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008000645-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2007098961-A1 | 4, 5, 6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| US-7253205-B2 | Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-7253205-B2 | Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CYP11B1 48/4885CYP11B2 75/4885CYP1A2 834/4885 |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | CYP11B1 2439/4885CYP11B2 2227/4885CYP1A2 1018/4885 |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | CYP3A7, UGT2B7, CYP51A1 | CYP11B1 76/4885CYP11B2 56/4885CYP1A2 92/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | CYP11B1 2239/4885CYP11B2 1840/4885CYP1A2 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.